148 related articles for article (PubMed ID: 25650054)
1. Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis.
Oliveira MB; Calixto G; Graminha M; Cerecetto H; González M; Chorilli M
Biomed Res Int; 2015; 2015():396894. PubMed ID: 25650054
[TBL] [Abstract][Full Text] [Related]
2. Structural characterization and in vitro antioxidant activity of kojic dipalmitate loaded w/o/w multiple emulsions intended for skin disorders.
Gonçalez ML; Marcussi DG; Calixto GM; Corrêa MA; Chorilli M
Biomed Res Int; 2015; 2015():304591. PubMed ID: 25785265
[TBL] [Abstract][Full Text] [Related]
3. Oil-in-water lecithin-based microemulsions as a potential delivery system for amphotericin B.
Pestana KC; Formariz TP; Franzini CM; Sarmento VH; Chiavacci LA; Scarpa MV; Egito ES; Oliveira AG
Colloids Surf B Biointerfaces; 2008 Oct; 66(2):253-9. PubMed ID: 18676122
[TBL] [Abstract][Full Text] [Related]
4. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis.
Carneiro G; Santos DC; Oliveira MC; Fernandes AP; Ferreira LS; Ramaldes GA; Nunan EA; Ferreira LA
J Liposome Res; 2010 Mar; 20(1):16-23. PubMed ID: 19530897
[TBL] [Abstract][Full Text] [Related]
5. Structural properties induced by the composition of biocompatible phospholipid-based microemulsion and amphotericin B association.
Franzini CM; Pestana KC; Molina EF; Scarpa MV; do Egito ES; de Oliveira AG
J Biomed Nanotechnol; 2012 Apr; 8(2):350-9. PubMed ID: 22515088
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of new microemulsion-based hydrogel formulations for topical delivery of fluconazole.
Coneac G; Vlaia V; Olariu I; Muţ AM; Anghel DF; Ilie C; Popoiu C; Lupuleasa D; Vlaia L
AAPS PharmSciTech; 2015 Aug; 16(4):889-904. PubMed ID: 25591952
[TBL] [Abstract][Full Text] [Related]
7. Investigation of surfactant/cosurfactant synergism impact on ibuprofen solubilization capacity and drug release characteristics of nonionic microemulsions.
Djekic L; Primorac M; Filipic S; Agbaba D
Int J Pharm; 2012 Aug; 433(1-2):25-33. PubMed ID: 22579578
[TBL] [Abstract][Full Text] [Related]
8. Emulgel based on amphotericin B and bacuri butter (Platonia insignis Mart.) for the treatment of cutaneous leishmaniasis: characterization and in vitro assays.
Coêlho ES; Lopes GLN; Pinheiro IM; Holanda JNP; Alves MMM; Carvalho Nogueira N; Carvalho FAA; Carvalho ALM
Drug Dev Ind Pharm; 2018 Oct; 44(10):1713-1723. PubMed ID: 29961344
[TBL] [Abstract][Full Text] [Related]
9. Oral fluconazole treatment for extensive cutaneous leishmaniasis in an 11-year-old child.
Toubiana J; Armengaud JB; Dupouy Camet J; Gendrel D
Pediatr Infect Dis J; 2006 Nov; 25(11):1083-4. PubMed ID: 17072139
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of biocompatible isotropic and anisotropic oil-in-water colloidal dispersions as a new delivery system for methyl dihydrojasmonate antitumor drug.
da Silva GB; Scarpa MV; Rossanezi G; do Egito ES; de Oliveira AG
Int J Nanomedicine; 2014; 9():867-76. PubMed ID: 24596463
[TBL] [Abstract][Full Text] [Related]
11. Microemulsions as vehicles for topical administration of voriconazole: formulation and in vitro evaluation.
El-Hadidy GN; Ibrahim HK; Mohamed MI; El-Milligi MF
Drug Dev Ind Pharm; 2012 Jan; 38(1):64-72. PubMed ID: 21696340
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.
Alrajhi AA; Ibrahim EA; De Vol EB; Khairat M; Faris RM; Maguire JH
N Engl J Med; 2002 Mar; 346(12):891-5. PubMed ID: 11907288
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole for the treatment of cutaneous leishmaniasis.
Zvulunov A; Klaus S; Vardy D
N Engl J Med; 2002 Aug; 347(5):370-1; author reply 370-1. PubMed ID: 12151480
[No Abstract] [Full Text] [Related]
14. Cutaneous leishmaniasis in a child treated with oral fluconazole.
Sklavos AV; Walls T; Webber MT; Watson AB
Australas J Dermatol; 2010 Aug; 51(3):195-7. PubMed ID: 20695859
[TBL] [Abstract][Full Text] [Related]
15. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterization, sterility validation, and in vitro cell toxicity studies of microemulsions possessing potential parenteral applications.
Nesamony J; Zachar CL; Jung R; Williams FE; Nauli S
Drug Dev Ind Pharm; 2013 Feb; 39(2):240-51. PubMed ID: 22480266
[TBL] [Abstract][Full Text] [Related]
17. A study of microemulsions as prolonged-release injectables through in-situ phase transition.
Wu Z; Alany RG; Tawfeek N; Falconer J; Zhang W; Hassan IM; Rutland M; Svirskis D
J Control Release; 2014 Jan; 174():188-94. PubMed ID: 24316265
[TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
19. Trans-resveratrol-loaded nonionic lamellar liquid-crystalline systems: structural, rheological, mechanical, textural, and bioadhesive characterization and evaluation of in vivo anti-inflammatory activity.
Fonseca-Santos B; Satake CY; Calixto GMF; Dos Santos AM; Chorilli M
Int J Nanomedicine; 2017; 12():6883-6893. PubMed ID: 29066884
[TBL] [Abstract][Full Text] [Related]
20. Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole.
Daly K; De Lima H; Kato H; Sordillo EM; Convit J; Reyes-Jaimes O; Zerpa O; Paniz-Mondolfi AE
Clin Exp Dermatol; 2014 Aug; 39(6):708-12. PubMed ID: 24985142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
